The etiology of lower respiratory tract infections in people with diabetes

Pneumonologia i Alergologia Polska

Volumn 83, Issue 5, 2015, Pages 401-408

  Klekotka, Renata Barbara ^a   Mizgała, Elżbieta ^a   Król, Wojciech ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Diabetes mellitus; Influenza; Mycosis; Streptococcus pneumoniae; Tuberculosis

Indexed keywords

COMMUNITY-ACQUIRED INFECTIONS; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HOSPITALIZATION; HUMAN; IMMUNIZATION; IMMUNOLOGY; INFLUENZA, HUMAN; MALE; MICROBIOLOGY; MONOCYTE; PATHOLOGY; PNEUMONIA; PROGNOSIS; RESPIRATORY TRACT INFECTIONS; TUBERCULOSIS, PULMONARY; VIROLOGY;

COMMUNITY-ACQUIRED INFECTIONS; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HOSPITALIZATION; HUMANS; IMMUNIZATION; INFLUENZA, HUMAN; MALE; MONOCYTES; PNEUMONIA; PROGNOSIS; RESPIRATORY TRACT INFECTIONS; TUBERCULOSIS, PULMONARY;

EID: 84941196412     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: 10.5603/PiAP.2015.0065     Document Type: Review

References (43)

1. Mizgerd JP. Lung infection-a public health priority. PLoS Med 2006; 3: e76.
2. Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA 1999; 281: 61-66.
3. Zhang X, Wang R, Di X, Liu B, Liu Y. Different microbiological and clinical aspects of lower respiratory tract infections between China and European/American countries. J Thorac Dis 2014; 6: 134-142. doi: 10.3978/j.issn.2072-1439.2014.02.02
4. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab 2012; 16: 27-36. doi: 10.4103/2230-8210.94253.
5. Kornum JB, Thomsen RW, Riis A, Lervang HH, Schønheyder HC, Sørensen HT. Type 2 diabetes and pneumonia outcomes: A population-based cohort study. Diabetes Care 2007; 30: 2251-2257.
6. Peleg AY, Weerarathna T, McCarthy JS, Davis TM. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev 2007; 23: 3-13.
7. Price CL, Al Hassi HO, English NR, Blakemore AI, Stagg AJ, Knight SC. Methylglyoxal modulates immune responses: relevance to diabetes. J Cell Mol Med 2010; 14: 1806-1815. doi: 10.1111/j.1582-4934.2009.00803.x.
8. Lydyard PM, Whelan A, Fanger MW. Krótkie wykłady. Immunologia. Wydawnictwo Naukowe PWN SA, Warszawa 2008; 97-103.
9. Bartlett JG, Dowell SF, Mandell LA et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347-382.
10. Niżankowska-Mogilnicka E (ed.). Choroby układu oddechowego. In: Szczeklik A (ed.). Choroby wewnętrzne. Stan wiedzy na rok 2010. Medycyna Praktyczna, Kraków 2010: 519-749.
11. Liu Y, Chen MJ, Zhao TM et al. Causative agent distribution and antibiotic therapy assessment among adult patients with community acquired pneumonia in Chinese urban population. BMC Infect Dis 2009; 9: 31. doi: 10.1186/1471-2334-9-31.
12. Papanicolaou GA, Severe influenza and S. aureus pneumonia: for whom the bell tolls? Virulence 2013; 4: 666-668. doi: 10.4161/viru.26957.
13. Carrillo-Marquez MA, Hulten KG, Hammerman W et al. USA 300 is the predominant genotype causing Staphylococcus aureus septic arthritis in children. Pediatr. Infect Dis J 2009; 28: 1076-1080. doi: 10.1097/INF.0b013e3181adbcfe.
14. Liu YN, Chen MJ, Zhao TM et al. A multicentre study on the pathogenic in 665 adult patients with community-acquired pneumonia in cities of China. Zhonghua Jie He He Hu Xi Za Zhi 2006; 29: 3-8.
15. Jones RN, Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010; 51: 81-87. doi: 10.1086/653053.
16. Ehrlich SF, Charles P, Quesenberry CP, Van Den Eeden SK, Shan J, Ferrara A. Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care 2010; 33: 55-60. doi: 10.2337//dc09-0880.
17. Stanowisko Polskiego Towarzystwa Diabetologicznego. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2014. Diabet Klin 2014; 3: A.
18. Barros MM, Cartagena SC, Bavestrello FL. Prevention of community- acquired pneumonia in adults. Rev Chilena Infectol 2005; 22: 67-74.
19. Malley R, Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development. J Mol Med 2010; 88: 135-142. doi: 10.1007/s00109-009-0579-4.
20. Schenkein JG, Park S, Nahm MH. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine 2008; 26: 5521-5526. doi: 10.1016/j.vaccine.2008.07.071.
21. Nam JS, Kim AR, Yoon JC et al. The humoral immune response to the inactivated influenza A (H1N1) monovalent vaccine in patients with type 2 diabetes mellitus in Korea Diabet Med 2011; 28: 815-817. doi: 10.1111/j.1464-5491.2011.03255.x.
22. Mathews CE, Brown EL, Martinez PJ et al. Impaired function of antibodies to pneumococcal surface protein A but not to capsular polysaccharide in Mexican American adults with type 2 diabetes mellitus. Clin Vaccine Immunol 2012; 19: 1360-1369. doi: 10.1128/CVI.00268-12.
23. Mrukowicz J. Wybrane choroby wirusowe. In: Szczeklik A (ed.). Choroby wewnętrzne. Stan wiedzy na rok 2010. Medycyna Praktyczna, Kraków 2010: 2089-2095.
24. Miller AC, Subranian RA, Safi F, Sinert R, Zehtabchi S. Elamin EM. Influenza A 2009 (H1N1) virus in admitted and critically ill patients. J Intensive Care Med 2011; 27: 25-31. doi: 10.1177/0885066610393626.
25. Rodríguez-Valero M, Prado Calleros HM, Bravo Escobar GA et al. Difference between early clinical features of swine origin A H1N1 influenza confirmed and not confirmed infection in Mexico J Infect Dev Ctries 2012; 6: 302-310.
26. Jain S, Kamimoto L, Bramley AM et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 12: 1935-1944. doi: 10.1056/NEJMoa0906695.
27. Restrepo BI, Camerlin AJ, Rahbar MH et al. Cross-sectional assessment reveals high diabetes prevalence among newly-diagnosed tuberculosis cases. Bull World Health Organ 2011; 89: 352-359. doi: 10.2471/BLT.10.085738.
28. Harries AD, Lin Y, Satyanarayana S et al. The looming epidemic of diabetes-associated tuberculosis: learning lessons from the HIV-associated tuberculosis. Inter J Tuberc. Lung Dis 2011; 15: 1436-1445. doi: 10.5588/ijtld.11.0503.
29. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: Convergence of two epidemics. Lancet Infect Dis 2009; 9: 737-746. doi: 10.1016/S1473-3099(09)70282-8.
30. Ruslami R, Aarniutse RE, Alisjahbana B, van der Ven AJ, van Crevel R. Implications of the global increase of diabetes for tuberculosis control and patient care. Trop Med Int Health 2010; 15: 1289-1299. doi: 10.1111/j.1365-3156.2010.02625.x.
31. Restrepo BI, Schlesinger LS. Host-pathogen interactions in tuberculosis patients with type 2 diabetes mellitus. Tuberculosis 2013; 93: 10-14. doi: 10.1016/S1472-9792(13)70004-0.
32. Fabri M, Stenger S, Shin DM et al. Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages. Sci Transl Med 2011; 3: 104ra102. doi: 10.1126/scitranslmed.3003045.
33. Guirado E, Schlesinger LS, Kaplan G. Macrophages in tuberculosis: friend or foe. Semin Immunopathol 2013; 35: 563-583. doi: 10.1007/s00281-013-0388-2.
34. Baker MA, Harries AD, Jeon CY et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med 2011; 9: 81. doi: 10.1186/1741-7015-9-81.
35. Gomez DI, Twahirwa M, Schlesinger LS, Restrepo BI. Reduced Mycobacterium tuberculosis association with monocytes from diabetes patients that have poor glucose control. Tuberculosis 2013; 93: 192-197. doi: 10.1016/j.tube.2012.10.003.
36. Restrepo BI, Twahirwa M, Rahbar MH, Schlesinger LS. Phagocytosis via complement or Fc-gamma receptors is compromised in monocytes from type 2 diabetes patients with chronic hyperglycemia. PLoS One 2014; 26: 9;e92977. doi: 10.1371/journal.pone.0092977.
37. Higa M. Clinical epidemiology of fungal infection in diabetes. Nihon Rinsho 2008; 66: 2239-2244.
38. Liu YN, She DY, Sun TY et al. A multicentre retrospective study of pulmonary mycosis clinically proven from 1998 to 2007. Zhonghua Jie He He Hu Xi Za Zhi 2011; 34: 86-90.
39. Ohba H, Miwa S, Shirai M, Kanai M, Eifuku T, Suda T, Hayakawa H, Chida K. Clinical characteristics and prognosis of chronic pulmonary aspergillosis. Respir Med 2012; 106: 724-729. doi: 10.1016/j.rmed.2012.01.014.
40. Kurnatowski P. Farmakoterapia grzybiczego zapalenia zatok przynosowych. Otolaryngologia 2010; 9: 13-17.
41. Kim MJ, Park PW, Ahn JY et al. Fatal pulmonary mucormycosis caused by Rhizopus microsporus in a patient with diabetes. Ann Lab Med 2014; 34: 76-79. doi: 10.3343/alm.2014.34.1.76.
42. Rajagopalan S. Serious infections in elderly patients with diabetes mellitus. Clin Infect Dis 2005; 40: 990-996.
43. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004; 10: 31-47.